Skip to main content
. Author manuscript; available in PMC: 2008 Mar 1.
Published in final edited form as: Clin Cancer Res. 2003 Aug 1;9(8):2973–2980.

Table 4.

Assay for antipeptide and antitumor reactivity in PBMCs from a patient immunized with fowlpox virus encoding modified full-length gp100 (rF-Mgp100)a

  Stimulator in assay
  T2 T2 T2 T2 526-mel 624-mel 888-mel 938-mel
Peptide used for In vitro sensitizationb In vitro sensitizationb   (209–217) (280–288) (154–262) (A2+) (A2+) (A2−)
Patient A                
  gp100:209–217 150c 382d 140 142 148 199 160 82
  gp100:209–217 (210M) 71 711 53 57 56 67 60 42
  gp100:280–288 76 68 3836 72 217 310 74 52
  gp100:280–288 (288V) 105 87 4482 98 210 319 97 69
  gp100:154–162 96 77 82 82 63 66 84 53
Patient B                
  gp100:209–217 85 683 64 51 13 24 21 14
  gp100:209–217 (210M) 810 1677 604 519 35 54 23 13
  gp100:280–288 226 217 2147 213 146 150 27 37
  gp100:280–288 (288V) 569 562 6803 604 175 203 42 31
  gp100:154–162 66 72 74 72 6 4 15 9
a

Fowlpox virus encoding gp100 with amino acid modifications 210M and 288V.

b

PBMCs cultured with 1 µm of each of the five peptides for 12 days as described in “Materials and Methods.”

c

Secretion of IFN-γ in an 18-h coculture assay. Values are given as pg IFN-γ/ml.

d

Underlined values are those judged to be positive results defined as greater than 100 pg/ml and at least twice greater than background (i.e. T2 alone).